Verona Pharma Plc Overview
Verona Pharma Plc Target Price
Analysts' 12-month price predictions for VRNA.
Get informed when a big investor buys or sells
+ FollowShare Price
$106.91
Average Target Price
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-07-14 | H.C. WainwrightRaghuram Selvaraju | $107 |  0.1% upside |  |
| 2025-06-30 | Wolfe Research | $170 | 59% upside | |
| 2025-06-23 | Piper Sandler | $160 | 49.7% upside | |
| 2025-04-21 | Cantor Fitzgerald | $80 |  25.2% downside | |
| 2025-02-28 | Roth Capital | $83 | 22.4% downside | |
| 2025-02-28 | H.C. Wainwright | $75 | 29.8% downside | |
| 2025-01-10 | Roth CapitalBoobalan Pachaiyappan | $68 | 36.4% downside | |
| 2025-01-08 | Wells FargoTiago Fauth | $74 | 30.8% downside | |
| 2024-11-05 | H.C. WainwrightRaghuram Selvaraju | $42 | 60.7% downside | |
| 2024-07-22 | Canaccord GenuityEdward Nash | $37 | 65.4% downside | |
| 2024-06-27 | H.C. WainwrightRaghuram Selvaraju | $36 | 66.3% downside | |
| 2024-05-28 | JefferiesAndrew Tsai | $38 | 64.5% downside | |
| 2024-04-16 | Piper SandlerYasmeen Rahimi | $36 | 66.3% downside | |
| 2022-12-21 | H.C. Wainwright | $32 | 70.1% downside | |
| 2022-12-20 | WedbushAndreas Argyrides | $30 | 71.9% downside | |
| 2022-12-20 | Truist Financial | $28 | 73.8% downside | |
| 2022-12-20 | BTIG | $26 | 75.7% downside | |
| 2022-08-30 | Canaccord GenuityEdward Nash Nash | $27 | 74.7% downside | |
| 2022-08-30 | WedbushLiana Moussatos Moussatos | $23 | 78.5% downside | |
| 2022-08-30 | H.C. WainwrightRaghuram Selvaraju Selvaraju | $30 | 71.9% downside | |